{"doi":"10.3389/fendo.2023.1275813","title":"Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [177Lu]Lu-DOTA-TATE therapy","abstract":"Purpose While there are reports of treatment-related endocrine disruptions and catecholamine surges in pheochromocytoma/paraganglioma (PPGL) patients treated with [ 177 Lu]Lu-DOTA-TATE therapy, the spectrum of these abnormalities in the immediate post-treatment period (within 48 hours) has not been previously evaluated and is likely underestimated. Methods The study population included patients (≥18 years) enrolled in a phase 2 trial for treatment of somatostatin receptor (SSTR)-2+ inoperable/metastatic pheochromocytoma/paraganglioma with [ 177 Lu]Lu-DOTA-TATE (7.4 GBq per cycle for 1 – 4 cycles). Hormonal measurements [adrenocorticotropic hormone (ACTH), cortisol, thyroid stimulating hormone (TSH), free thyroxine (FT4), follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone, estradiol, growth hormone, prolactin], catecholamines, and metanephrines were obtained on days-1, 2, 3, 30, and 60 per cycle as per trial protocol, and were retrospectively analyzed. Results Among the 27 patients (age: 54 ± 12.7 years, 48.1% females) who underwent hormonal evaluation, hypoprolactinemia (14.1%), elevated FSH (13.1%), and elevated LH (12.5%) were the most frequent hormonal abnormalities across all 4 cycles combined. On longitudinal follow-up, significant reductions were noted in i. ACTH without corresponding changes in cortisol, ii. TSH, and FT4, and iii. prolactin at or before day-30 of [ 177 Lu]Lu-DOTA-TATE. No significant changes were observed in the gonadotropic axis and GH levels. Levels of all hormones on day-60 were not significantly different from day-1 values, suggesting the transient nature of these changes. However, two patients developed clinical, persistent endocrinopathies (primary hypothyroidism: n=1 male; early menopause: n=1 female). Compared to day-1, a significant % increase in norepinephrine, dopamine, and normetanephrine levels were noted at 24 hours following [ 177 Lu]Lu-DOTA-TATE dose and peaked within 48 hours. Conclusions [ 177 Lu]Lu-DOTA-TATE therapy is associated with alterations in endocrine function likely from radiation exposure to SSTR2+ endocrine tissues. However, these changes may sometimes manifest as clinically significant endocrinopathies. It is therefore important to periodically assess endocrine function during [ 177 Lu]Lu-DOTA-TATE therapy, especially among symptomatic patients. Clinical trial registration https://clinicaltrials.gov/ct2/show/NCT03206060?term=NCT03206060&draw=2&rank=1 , identifier NCT03206060.","journal":"Frontiers in Endocrinology","year":2023,"id":358746,"datarank":0.4403854116943852,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.06764941422618508,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.06764941422618508,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":5,"citers_with_citation_signal":3,"citers_with_endowment":3,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9532,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03206060"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":764427,"name":"Mohammad Al-Jundi","orcid":"0000-0002-7076-6488","position":1,"is_corresponding":false},{"id":355656,"name":"Sungyoung Auh","orcid":"0000-0002-3901-0869","position":2,"is_corresponding":false},{"id":302290,"name":"Abhishek Jha","orcid":"0000-0001-9161-0450","position":3,"is_corresponding":false},{"id":765082,"name":"Joy Zou","orcid":null,"position":4,"is_corresponding":false},{"id":1109506,"name":"Inna Shamis","orcid":null,"position":5,"is_corresponding":false},{"id":377912,"name":"Leah Meuter","orcid":null,"position":6,"is_corresponding":false},{"id":351472,"name":"Marianne Knue","orcid":"0000-0002-8898-8767","position":7,"is_corresponding":false},{"id":110339,"name":"Barış Türkbey","orcid":"0000-0003-0853-6494","position":8,"is_corresponding":false},{"id":289934,"name":"Liza Lindenberg","orcid":"0000-0002-8514-0648","position":9,"is_corresponding":false},{"id":403782,"name":"Esther Mena","orcid":"0000-0003-0015-0597","position":10,"is_corresponding":false},{"id":308731,"name":"Jorge A. Carrasquillo","orcid":"0000-0002-8513-5734","position":11,"is_corresponding":false},{"id":1109119,"name":"Yating Teng","orcid":"0000-0001-6568-9783","position":12,"is_corresponding":false},{"id":70229,"name":"Karel Pacák","orcid":"0000-0002-3541-3767","position":13,"is_corresponding":false},{"id":255444,"name":"Joanna Kłubo-Gwieździńska","orcid":"0000-0001-8633-4420","position":14,"is_corresponding":false},{"id":302291,"name":"Jaydira Del Rivero","orcid":"0000-0001-9710-4030","position":15,"is_corresponding":false},{"id":464208,"name":"Frank I. Lin","orcid":"0000-0003-3539-1454","position":16,"is_corresponding":false},{"id":108961,"name":"Sriram Gubbi","orcid":"0000-0002-9263-1381","position":0,"is_corresponding":true}],"reference_count":36,"raw_metadata":null,"created_at":"2026-07-19T01:13:48.379546Z","pmid":"37886645","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}